MCRB

Seres Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · serestherapeutics.com

$7.69

Mkt Cap $74.1M

52w Low $6.53 4.9% of range 52w High $29.98

50d MA $8.66 200d MA $14.49

P/E (TTM) 11.9x

EV/EBITDA -1.9x

P/B 1.5x

Debt/Equity 1.9x

ROE 12.9%

P/FCF 152.4x

RSI (14) —

ATR (14) —

Beta 0.26

50d MA $8.66

200d MA $14.49

Avg Volume 68.7K

About

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). I…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	-2.39	-1.89	+20.9%	9.05	-0.6%	-4.6%	-4.3%	+3.8%	-0.2%	+0.3%	—
Nov 5, 2025	AMC	0.05	0.94	+1780.0%	12.70	+1.3%	+9.1%	+10.4%	+10.6%	+17.3%	+26.1%	—
Aug 6, 2025	AMC	-2.72	-2.27	+16.5%	13.79	+2.9%	+10.9%	+3.0%	+5.4%	+12.0%	+15.8%	—
May 7, 2025	AMC	-0.67	-2.24	-234.3%	8.29	-3.5%	-16.0%	-14.8%	-4.9%	-11.1%	-18.3%	—
Mar 13, 2025	AMC	-0.17	-0.32	-88.2%	12.77	+1.8%	+8.1%	+15.6%	+16.9%	+22.1%	+14.6%	—
Nov 13, 2024	AMC	-5.00	-6.60	-32.0%	11.80	+0.0%	+0.3%	-6.9%	-1.9%	+16.7%	+38.0%	—
Aug 13, 2024	AMC	-5.60	-4.40	+21.4%	16.56	+6.3%	+9.1%	+6.9%	+6.3%	+14.6%	+4.0%	—
May 8, 2024	AMC	-7.20	-5.40	+25.0%	14.99	+2.7%	+37.4%	+36.1%	+28.8%	+19.5%	+27.8%	—
Mar 5, 2024	AMC	-8.00	-6.40	+20.0%	21.20	-0.9%	-4.7%	-7.5%	-8.4%	-18.9%	-27.1%	—
Nov 2, 2023	AMC	-9.40	-7.40	+21.3%	18.65	+5.1%	+39.4%	+22.3%	+30.8%	+11.5%	+8.3%	—
Aug 8, 2023	AMC	11.00	7.20	-34.5%	85.80	-1.6%	-6.1%	-8.4%	-9.8%	-10.5%	-12.6%	—
May 9, 2023	AMC	-11.40	-11.40	+0.0%	111.40	-0.4%	-4.7%	-1.6%	-7.9%	-4.3%	-8.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 13	Canaccord Genuity	Maintains	Buy → Buy	—	$9.05	$9.00	-0.6%	-4.6%	-4.3%	+3.8%	-0.2%	+0.3%
Sep 24	Canaccord Genuity	Maintains	Buy → Buy	—	$17.56	$17.89	+1.9%	+10.4%	+7.6%	+7.8%	+6.4%	+9.6%
May 8	Chardan Capital	Downgrade	Buy → Neutral	—	$8.29	$8.00	-3.5%	-16.0%	-14.8%	-4.9%	-11.1%	-18.3%
Mar 20	Chardan Capital	Maintains	Buy → Buy	—	$15.59	$15.32	-1.7%	-6.1%	-8.7%	-8.5%	-8.7%	-6.4%
Mar 14	Goldman Sachs	Maintains	Sell → Sell	—	$12.77	$13.00	+1.8%	+8.1%	+15.6%	+16.9%	+22.1%	+14.6%
Nov 14	Canaccord Genuity	Maintains	Buy → Buy	—	$11.80	$11.80	+0.0%	+0.3%	-6.9%	-1.9%	+16.7%	+38.0%
Nov 13	Chardan Capital	Maintains	Buy → Buy	—	$13.28	$13.00	-2.1%	-11.1%	-10.8%	-17.2%	-12.8%	+3.7%
Oct 24	JP Morgan	Downgrade	Neutral → Underweight	—	$15.14	$15.14	+0.0%	-6.2%	-6.9%	-7.5%	+1.8%	+3.4%
Sep 13	Canaccord Genuity	Maintains	Buy → Buy	—	$19.20	$18.80	-2.1%	+4.1%	+6.2%	+14.6%	+9.4%	+9.4%
Aug 14	Chardan Capital	Maintains	Buy → Buy	—	$16.56	$17.60	+6.3%	+9.1%	+6.9%	+6.3%	+14.6%	+4.0%
Aug 14	Canaccord Genuity	Maintains	Buy → Buy	—	$16.56	$17.60	+6.3%	+9.1%	+6.9%	+6.3%	+14.6%	+4.0%
Jun 7	Oppenheimer	Downgrade	Outperform → Perform	—	$17.06	$15.80	-7.4%	-28.0%	-13.2%	-6.9%	-12.6%	-16.7%
Jun 7	Canaccord Genuity	Maintains	Buy → Buy	—	$17.06	$15.80	-7.4%	-28.0%	-13.2%	-6.9%	-12.6%	-16.7%
May 9	Oppenheimer	Maintains	Outperform → Outperform	—	$14.99	$15.40	+2.7%	+37.4%	+36.1%	+28.8%	+19.5%	+27.8%
May 8	Chardan Capital	Maintains	Buy → Buy	—	$22.20	$15.60	-29.7%	-32.5%	-7.2%	-8.1%	-13.1%	-19.3%
Mar 6	Chardan Capital	Maintains	Buy → Buy	—	$21.20	$21.00	-0.9%	-4.7%	-7.5%	-8.4%	-18.9%	-27.1%
Mar 6	Oppenheimer	Maintains	Outperform → Outperform	—	$21.20	$21.00	-0.9%	-4.7%	-7.5%	-8.4%	-18.9%	-27.1%
Jan 16	Oppenheimer	Maintains	Outperform → Outperform	—	$24.00	$24.60	+2.5%	+2.5%	+7.5%	+2.5%	+2.5%	+4.2%
Nov 3	Goldman Sachs	Maintains	Sell → Sell	—	$18.65	$19.60	+5.1%	+39.4%	+22.3%	+30.8%	+11.5%	+8.3%
Apr 28	Chardan Capital	Maintains	Buy → Buy	—	$106.40	$103.80	-2.4%	-8.3%	-8.5%	-12.2%	-1.9%	+2.4%
Apr 21	JP Morgan	Maintains	Neutral → Neutral	—	$126.60	$127.00	+0.3%	+1.7%	+2.7%	-2.7%	+1.1%	-16.0%
Mar 21	Canaccord Genuity	Maintains	Buy → Buy	—	$109.80	$112.00	+2.0%	+10.9%	+6.7%	+3.3%	+3.6%	-0.5%
Mar 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$108.00	$108.60	+0.6%	+10.0%	-1.9%	-2.6%	-0.4%	+3.1%
Mar 8	Chardan Capital	Maintains	Buy → Buy	—	$108.00	$108.60	+0.6%	+10.0%	-1.9%	-2.6%	-0.4%	+3.1%
Mar 8	Canaccord Genuity	Maintains	Buy → Buy	—	$108.00	$108.60	+0.6%	+10.0%	-1.9%	-2.6%	-0.4%	+3.1%
Feb 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$108.80	$107.80	-0.9%	-1.8%	-0.2%	-0.4%	-0.9%	-1.3%
Sep 7	Piper Sandler	Maintains	Overweight → Overweight	—	$108.00	$109.80	+1.7%	+17.0%	+24.3%	+19.4%	+28.3%	+24.8%
May 23	Piper Sandler	Maintains	Overweight → Overweight	—	$71.40	$74.20	+3.9%	-7.6%	-14.8%	-15.7%	-16.0%	-10.6%
Jul 23	Chardan Capital	Maintains	Buy → Buy	—	$159.00	$158.80	-0.1%	-7.0%	-3.4%	-10.4%	-5.7%	-12.1%
Jul 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$159.00	$158.80	-0.1%	-7.0%	-3.4%	-10.4%	-5.7%	-12.1%
Jul 23	Goldman Sachs	Downgrade	Neutral → Sell	—	$159.00	$158.80	-0.1%	-7.0%	-3.4%	-10.4%	-5.7%	-12.1%
Jul 23	Oppenheimer	Maintains	Outperform → Outperform	—	$159.00	$158.80	-0.1%	-7.0%	-3.4%	-10.4%	-5.7%	-12.1%
Jul 23	Canaccord Genuity	Maintains	Buy → Buy	—	$159.00	$158.80	-0.1%	-7.0%	-3.4%	-10.4%	-5.7%	-12.1%
May 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$429.60	$429.40	-0.0%	-1.7%	+2.4%	-3.5%	-6.7%	+3.8%
Mar 5	Chardan Capital	Upgrade	Neutral → Buy	—	$362.20	$384.60	+6.2%	+5.2%	-2.0%	+12.0%	+13.1%	+25.3%
Dec 23	JMP Securities	Maintains	Market Perform → Perform	—	$495.60	$515.40	+4.0%	+3.0%	-2.0%	-6.2%	-1.2%	+5.9%
Sep 21	Canaccord Genuity	Maintains	Buy → Buy	—	$513.00	$507.40	-1.1%	+2.4%	+3.3%	-0.7%	-1.6%	+2.8%
Sep 18	Chardan Capital	Downgrade	Buy → Neutral	—	$537.20	$523.20	-2.6%	-4.5%	-2.2%	-1.4%	-5.2%	-6.0%
Aug 18	Piper Sandler	Maintains	Overweight → Overweight	—	$523.20	$540.20	+3.2%	-7.3%	-4.4%	-3.7%	-6.0%	-12.0%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$454.00	$447.80	-1.4%	-11.7%	+3.8%	+25.9%	+20.1%	+15.2%
Aug 11	Jefferies	Upgrade	Hold → Buy	—	$454.00	$447.80	-1.4%	-11.7%	+3.8%	+25.9%	+20.1%	+15.2%
Aug 11	Chardan Capital	Maintains	Buy → Buy	—	$454.00	$447.80	-1.4%	-11.7%	+3.8%	+25.9%	+20.1%	+15.2%
Mar 31	Oppenheimer	Maintains	Outperform → Outperform	—	$74.00	$73.80	-0.3%	-3.5%	-11.1%	-14.6%	-17.8%	-10.3%
Apr 30	Jefferies	Maintains	Hold → Hold	—	$139.00	$137.20	-1.3%	-5.9%	-12.1%	-23.0%	-27.5%	-27.1%
Oct 22	Chardan Capital	Maintains	Buy → Buy	—	$130.60	$139.60	+6.9%	+1.1%	+0.8%	-2.3%	-3.8%	-5.4%
Aug 3	Bank of America	Downgrade	Neutral → Underperform	—	$148.20	$145.60	-1.8%	+1.9%	+0.3%	+3.1%	+9.3%	+9.2%
Aug 3	BofA Securities	Downgrade	Neutral → Underperform	—	$148.20	$145.60	-1.8%	+1.9%	+0.3%	+3.1%	+9.3%	+9.2%
Oct 13	Oppenheimer	Maintains	Outperform → Outperform	—	$217.40	$226.00	+4.0%	+1.1%	-0.6%	+0.6%	-3.9%	-5.2%
Oct 6	Seaport Global	Maintains	Buy → Buy	—	$240.00	$245.60	+2.3%	-0.7%	-3.9%	-4.2%	-8.6%	-9.4%
Dec 16	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$184.00	$188.80	+2.6%	+6.1%	+8.7%	+9.7%	+7.2%	+6.0%